Robert F. Kennedy Jr. on vaccines: what the evidence says · JRE #1999

What the evidence says 01 / RECORD

Whole-cell DTP vaccine was used in the United States from the 1940s through the 1990s; U.S. health authorities (the Institute of Medicine, per CDC/ACIP) did conclude the whole-cell pertussis component was causally linked to rare acute encephalopathy, and CDC confirms no whole-cell DTP vaccine is currently licensed in the U.S., having been fully replaced by the acellular DTaP vaccine in the 1990s because of safety concerns. However, the transition was a phased shift to a lower-reactogenicity product as it became available, not a recall or ban triggered by a documented 1-in-300 death/brain-damage rate; that specific ratio does not appear in CDC, WHO, or peer-reviewed estimates of serious whole-cell DTP adverse events. CDC's own cited postlicensure surveillance (Japan, 1970-1974) found acute encephalopathy/encephalitis (including deaths) at a rate of about 7.6 cases per 10 million doses under whole-cell DTP, roughly 1 in 1.3 million, several orders of magnitude rarer than 1 in 300. Whole-cell DTP-containing vaccines remain WHO-prequalified and are still used in many low- and middle-income countries, including through Gavi, the Vaccine Alliance (which the Gates Foundation helps fund), because international health bodies continue to judge their benefit-risk profile favorable given pertussis's high fatality risk in unvaccinated infants; this reflects ongoing global vaccine policy, not a product banned for a proven safety reason and then covertly redirected to Africa. The claim mixes an accurate underlying fact (the U.S. did move away from whole-cell DTP) with a fabricated injury rate and an inaccurate characterization of why and how the transition occurred and of current WHO/Gavi-supported immunization programs.